Login to Your Account

Financings NEWS

Things may soon be looking up for liposomal anthracycline L-annamycin, in the works for AML, if Moleculin Biotech Inc. has anything to say about it.

Theravance Biopharma Inc. priced an upsized $94.1 million public offering on Friday, saying it would sell about 4.77 million shares at $21 each as it moves to build a strong balance sheet capable of supporting two key development programs.

LONDON – The U.S. technology commercialization specialist Allied Minds plc has raised $80 million from U.K. investors to fund drug discovery programs in-licensed through its partnership with Bristol-Myers Squibb Co.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: